<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor etwa 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4903183-ryder-system-inc-r-presents-at-bank-of-america-33rd-annual-industrials-transportation-and">Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor etwa 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/biotechnology/bioinvents-tnfr2-antibody-bi-1808-shows-strong-activity-and-immune-activation-as-sing-1166147">BioInvent&#39;s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)</a>
    </div>

      <div class="me-0 me-md-5">
        40%   objective response rate ( ORR) as single agent in heavily pre - treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL) Durable responses observed, including a complete response lasting over two years and ongoing 50% ORR in combination with KEYTRUDA® (pembrolizumab) Targeting TNFR2 drove robust immune activation, with depletion of regulatory T cells and increased CD8+ T cell infil...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor etwa 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/biotechnology/bioinvent-to-present-clinical-data-on-fc%ce%b3riib-antibody-bi-1206-triplet-combination-th-1166148">BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026</a>
    </div>

      <div class="me-0 me-md-5">
        LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB (&quot;BioInvent&quot;) (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin&#39;s lymphoma (NHL) at the 31st European Hematolog...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor etwa 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/ensysce-biosciences-announces-expansion-of-patent-protection-for-grou-1165814">Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology</a>
    </div>

      <div class="me-0 me-md-5">
        ~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (&quot;Ensysce&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor etwa 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/quarterly-report-q1-2026-orviglancer-approaching-transformative-miles-1166092">Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones</a>
    </div>

      <div class="me-0 me-md-5">
        MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company&#39;s website: Financial Reports - ASCELIA KEY EVENTS IN Q1 2026 Abstract with Orviglance data has been accepted for oral presentation at the annual radiology congress ESGAR 2026 Management changes: Anton Hansson star...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260505311547/en/Ryder-CEO-to-Address-Bank-of-America-Securities-Industrials-Transportation-and-Airlines-Key-Leaders-Conference/">Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference</a>
    </div>

      <div class="me-0 me-md-5">
        MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chief Executive Officer John Diez will present a company update at the 2026 Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference. Who:  Ryder System, Inc. Chief Executive Officer John Diez What: Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260429257619/en/Ryder-Declares-Quarterly-Cash-Dividend/">Ryder Declares Quarterly Cash Dividend</a>
    </div>

      <div class="me-0 me-md-5">
        MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder declares quarterly cash dividend.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 2 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260429856889/en/Ryder-Authorizes-New-Discretionary-Plan-to-Repurchase-Shares/">Ryder Authorizes New Discretionary Plan to Repurchase Shares</a>
    </div>

      <div class="me-0 me-md-5">
        MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder authorizes new discretionary plan to repurchase shares.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Ryder-System-US7835491082/load_more?page=4">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>